Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | KL. Jhaveri, V Makker, XV Wang, AP. Chen, K Flaherty, BA. Conley, PJ. O'Dwyer, PM. Williams, SR. Hamilton, L Harris, L McShane, L Rubinstein, RJ Gray, S Li, EP. Mitchell, D Patton, J Moscow, JA. Zwiebel, CL. Arteaga, SW Luoh | ||||||||||||
Title | Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MAT | ||||||||||||
|
|||||||||||||
URL | https://meetinglibrary.asco.org/record/161669/abstract | ||||||||||||
Abstract Text | J Clin Oncol 36, 2018 (suppl; abstr 100) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|